FDA grants Novartis' Kymriah Priority Review for DLBCL

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to an sBLA for Kymriah tisagenlecleucel to

Read the full 181 word article

User Sign In